Scroll

norfloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibacterials, nalidixic acid derivatives	1967	70458-96-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: floxacin norfloxacine norphloxacine norfloxacin	A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. Molecular weight: 319.34 Formula: C16H18FN3O3 CLOGP: -0.53 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 72.88 ALOGS: -2.50 ROTB: 3 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

floxacin
norfloxacine
norphloxacine
norfloxacin

A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.

Molecular weight: 319.34
Formula: C16H18FN3O3
CLOGP: -0.53
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 72.88
ALOGS: -2.50
ROTB: 3

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	6.96 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.45 hours	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	35.79 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	35 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	29 %	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	1.88 L/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.75 mg/mL	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.13 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Oct. 31, 1986	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
International normalised ratio fluctuation	454.49	40.41	76	1775	2402	63484769
Bloody discharge	343.71	40.41	56	1795	1495	63485676
Lyme disease	292.66	40.41	55	1796	3394	63483777
Therapeutic product effect incomplete	147.71	40.41	72	1779	124984	63362187
Infection	124.26	40.41	79	1772	229094	63258077
Drug hypersensitivity	109.17	40.41	82	1769	310605	63176566
Drug intolerance	98.57	40.41	77	1774	308584	63178587
Iron deficiency	71.37	40.41	20	1831	7210	63479961
Pyramidal tract syndrome	58.55	40.41	10	1841	353	63486818
Platelet count increased	50.11	40.41	19	1832	17692	63469479

Showing 1 to 10 of 11 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic encephalopathy	63.25	33.38	20	743	14665	34941503
Hydrocholecystis	38.72	33.38	7	756	463	34955705
Tendon rupture	36.25	33.38	11	752	7001	34949167
Obsessive-compulsive disorder	34.29	33.38	10	753	5554	34950614
Tendonitis	33.39	33.38	11	752	9129	34947039

Showing 1 to 5 of 5 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
International normalised ratio fluctuation	426.68	30.57	77	2530	3377	79738404
Bloody discharge	324.16	30.57	56	2551	1897	79739884
Lyme disease	287.74	30.57	55	2552	3295	79738486
Therapeutic product effect incomplete	133.85	30.57	73	2534	141572	79600209
Infection	123.58	30.57	84	2523	241628	79500153
Drug intolerance	103.24	30.57	78	2529	264041	79477740
Drug hypersensitivity	101.07	30.57	81	2526	298835	79442946
Hepatic encephalopathy	72.83	30.57	28	2579	24138	79717643
Iron deficiency	57.40	30.57	19	2588	10635	79731146
Pyramidal tract syndrome	46.24	30.57	9	2598	588	79741193

Showing 1 to 10 of 15 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01MA06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones
ATC	J01RA13	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
ATC	J01RA14	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
ATC	S01AE02	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Fluoroquinolones
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:59517	DNA synthesis inhibitors
CHEBI has role	CHEBI:78298	environmental contaminants
FDA CS	M0023650	Quinolones
FDA EPC	N0000175937	Quinolone Antimicrobial

Showing 1 to 10 of 19 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Otitis externa	indication	3135009
Typhoid fever	indication	4834000	DOID:13258
Septicemia due to Escherichia coli	indication	9323009
Prostatitis	indication	9713002	DOID:14654
Infection due to Pseudomonas aeruginosa	indication	11218009
Gonorrhea	indication	15628003	DOID:7551
Enteric campylobacteriosis	indication	18081009
Infectious diarrheal disease	indication	19213003	DOID:13250
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615

Showing 1 to 10 of 243 entries

Previous1 2 3 4 5…25Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.98	acidic
pKa2	8.54	Basic
pKa3	1.37	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Gamma-aminobutyric acid receptor subunit alpha-3	Ion channel	P34903	GBRA3_HUMAN		IC50	6.29	WOMBAT-PK
Gamma-aminobutyric acid receptor subunit alpha-5	Ion channel	P31644	GBRA5_HUMAN		IC50	6.29	WOMBAT-PK
Gamma-aminobutyric acid receptor subunit alpha-4	Ion channel	P48169	GBRA4_HUMAN		IC50	6.29	WOMBAT-PK
Gamma-aminobutyric acid receptor subunit alpha-6	Ion channel	Q16445	GBRA6_HUMAN		IC50	6.29	WOMBAT-PK
DNA topoisomerase 2-beta	Enzyme	Q02880	TOP2B_HUMAN		IC50	6.22	WOMBAT-PK
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	4.75	CHEMBL
Gamma-aminobutyric acid receptor subunit alpha-1	Ion channel	P14867	GBRA1_HUMAN		IC50	6.29	WOMBAT-PK
Gamma-aminobutyric acid receptor subunit alpha-2	Ion channel	P47869	GBRA2_HUMAN		IC50	6.29	WOMBAT-PK
DNA topoisomerase 4 subunit A	Enzyme		PARC_ECOLI	INHIBITOR	IC50	5.29	WOMBAT-PK	CHEMBL
DNA gyrase subunit A	Enzyme		GYRA_ECOLI	INHIBITOR	IC50	6.05	WOMBAT-PK	CHEMBL

Showing 1 to 10 of 14 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
002881	NDDF
12408	IUPHAR_LIGAND_ID
387271008	SNOMEDCT_US
4019503	VUID
4019503	VANDF
4539	PUBCHEM_CID
49485009	SNOMEDCT_US
5105	INN_ID
5189	MMSL
7517	RXNORM

Showing 1 to 10 of 20 entries

Previous1 2Next

Pharmaceutical products:

None